Pyxis Oncology stock: Wells Fargo keeps USD 19.00 target for PYXS stock

Published on 10/23/2026 at 05:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Wells Fargo rates Pyxis Oncology stock Buy at a USD 19.00 target on October 16, 2026. The offering raised USD 110.0 million.

Funding and analyst signals

Wells Fargo retained a USD 19.00 price target and Buy rating on October 16, 2026.
The October 1, 2026 offering sold 36,047,919 common shares at USD 2.90 each.
Pyxis Oncology had a USD 108.3 million market capitalization as of October 22, 2026.

PYXS, US7473241013, Illustration mit AI erstellt.

Pyxis Oncology (US7473241013) secured USD 110.0 million in upfront gross proceeds when it closed its public offering on October 1, 2026, according to Pyxis Oncology. On October 16, 2026, Wells Fargo analyst Derek Archila reiterated a Buy rating and a USD 19.00 price target, Markets Insider reported.

Capital supports MICVO development

The financing gives the clinical-stage biotechnology company fresh capital for its cancer pipeline. The offering included 36,047,919 common shares priced at USD 2.90 and pre-funded warrants for 1,883,121 additional shares, according to Pyxis Oncology.

The transaction also included common warrants for 49,310,352 shares with an exercise price of USD 3.50. If those milestone-linked warrants are exercised in full for cash, total gross proceeds could reach USD 282.6 million, while the company expects overall survival data from its MICVO study in the first half of 2027.

What does the funding mean for risk?

The offering expands the potential funding pool but also increases the share count. Pyxis Oncology reported a GAAP net loss of USD 25.35 million, or USD 0.40 per diluted share, for the second quarter of 2026, according to Markets Insider. The financial profile therefore remains tied to clinical execution rather than product revenue.

Three dates shape the timeline

On September 9, 2026, Pyxis Oncology presented a MICVO clinical update; reported data included a 36 percent confirmed objective response rate and a 94 percent disease control rate in 33 evaluable patients, Tickeron reported. On October 1, 2026, the company closed the offering with USD 110.0 million in upfront proceeds. On October 16, 2026, Wells Fargo reiterated its USD 19.00 target.

Upcoming dates for PYXS

Pyxis Oncology is scheduled to report third-quarter 2026 results on November 2, 2026, according to MarketBeat. The company also expects overall survival data in the first half of 2027, according to the offering information carried by Quiver Quantitative.

Market value stays clinical

Pyxis Oncology had a USD 108.3 million market capitalization as of October 22, 2026. Its Nasdaq listing and biotechnology classification keep the valuation closely linked to MICVO milestones, financing terms and upcoming clinical disclosures.